The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global ophthalmic devices market size reached US$ 25.19 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 33.42 Billion by 2027, exhibiting a growth rate (CAGR) of 4.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Ophthalmic devices are medical equipment used for surgical diagnosis and vision correction. They comprise contact lenses, contact lens care products, diagnostics, implants, intraocular lenses (IOLs), lasers, phacoemulsification systems, artificial tears, and surgical instruments. They are used to diagnose and cure ocular abnormalities or deficits, and other eye diseases. They aid in making the eye-treatment procedure more convenient for patients and ophthalmologists by reducing treatment time and providing high-quality eye care. At present, due to the rising prevalence of ophthalmic diseases, such as cataracts and glaucoma, there is an increase in the demand for ophthalmic devices across the globe.
The growing reliance on digital devices, such as laptops, smartphones, computers and e-readers, represents one of the key factors driving the market. Moreover, there is a rise in the utilization of intraocular lenses (IOLs) to replace the natural lens of eyes for restoring both near and distant vision. This, along with the expanding healthcare industry, is propelling the growth of the market. In addition, the growing customer training and education among eye care professionals to cure eye diseases and associated complications is positively influencing the market. Besides this, key market players are extensively investing in research and development (R&D) activities for the development of novel devices to treat vision errors. This, coupled with the rising awareness about ophthalmic devices among individuals, is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the employment of micro-invasive glaucoma (MIGs) surgical implants for the treatment of mild to moderate glaucoma. In line with this, governments of several countries are undertaking initiatives to promote eye health, which is bolstering the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global ophthalmic devices market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, application and end use.
Breakup by Product Type:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Carl Zeiss Meditec AG, EssilorLuxottica SA, Haag-Streit Group, HOYA Surgical Optics GmbH (Hoya Corporation), Leica Microsystems GmbH (Danaher Corporation), Nidek Co Ltd., Topcon Corporation, Volk Optical Inc. and Ziemer Ophthalmic Systems AG.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Carl Zeiss Meditec AG, EssilorLuxottica SA, Haag-Streit Group, HOYA Surgical Optics GmbH (Hoya Corporation), Leica Microsystems GmbH (Danaher Corporation), Nidek Co Ltd., Topcon Corporation, Volk Optical Inc. and Ziemer Ophthalmic Systems AG.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at